Publication:
Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.

Loading...
Thumbnail Image

Date

2022-09-16

Authors

Garcia-de-Lucas, Maria Dolores
Miramontes-Gonzalez, Jose Pablo
Aviles-Bueno, Beatriz
Jimenez-Millan, Ana Isabel
Rivas-Ruiz, Francisco
Perez-Belmonte, Luis M

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Frontiers Research Foundation
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals. An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c 5%. After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use.

Description

MeSH Terms

Adult
Ambulatory Care Facilities
Body Weight
Diabetes Mellitus, Type 2
Glucagon-Like Peptides
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Retrospective Studies
Spain

DeCS Terms

Peso corporal
Pacientes ambulatorios
España
Estudio clínico
Diabetes Mellitus tipo 2

CIE Terms

Keywords

HbA1c, T2DM, Body weight, Once-weekly semaglutide, Real-world use

Citation

Garcia de Lucas MD, Miramontes-González JP, Avilés-Bueno B, Jiménez-Millán AI, Rivas-Ruiz F, Pérez-Belmonte LM. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain. Front Endocrinol (Lausanne). 2022 Sep 16;13:995646